1. Home
  2. IMKTA vs GLUE Comparison

IMKTA vs GLUE Comparison

Compare IMKTA & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ingles Markets Incorporated

IMKTA

Ingles Markets Incorporated

HOLD

Current Price

$85.75

Market Cap

1.7B

ML Signal

HOLD

Logo Monte Rosa Therapeutics Inc.

GLUE

Monte Rosa Therapeutics Inc.

HOLD

Current Price

$22.75

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMKTA
GLUE
Founded
1963
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Food Chains
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.7B
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
IMKTA
GLUE
Price
$85.75
$22.75
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$32.00
AVG Volume (30 Days)
110.2K
1.4M
Earning Date
05-11-2026
05-08-2026
Dividend Yield
0.74%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,334,032,609.00
$123,672,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$2.45
P/E Ratio
$15.91
$72.42
Revenue Growth
N/A
63.54
52 Week Low
$59.27
$4.12
52 Week High
$95.62
$25.77

Technical Indicators

Market Signals
Indicator
IMKTA
GLUE
Relative Strength Index (RSI) 36.84 52.14
Support Level $82.53 $17.35
Resistance Level $90.05 $25.45
Average True Range (ATR) 2.52 1.54
MACD -0.63 -0.25
Stochastic Oscillator 15.00 43.57

Price Performance

Historical Comparison
IMKTA
GLUE

About IMKTA Ingles Markets Incorporated

Ingles Markets Inc is a U.S.-based company that is principally engaged in operating a supermarket chain. The company operates the business in the southeast United States, mainly in Georgia, North Carolina, South Carolina, and Tennessee, with a few stores in Virginia and Alabama as well. The company locates its stores majorly in suburban areas, small towns, and neighborhood areas. It offers a broad range of goods, including food products, pharmacies, health and beauty care products, and general merchandise. The retail business contributes the majority of the company's revenue. The company's real estate ownership of a material portion of total stores enables it to generate rental income.

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).

Share on Social Networks: